This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Taranabant
DrugBank Accession Number
DB06624
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 515.96
Monoisotopic: 515.1587392
Chemical Formula
C27H25ClF3N3O2
Synonyms
  • Taranabant
External IDs
  • MK-0364
  • MK-0634

Pharmacology

Indication

Investigated for use/treatment in obesity.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Taranabant is combined with 1,2-Benzodiazepine.
AcebutololThe risk or severity of Tachycardia can be increased when Taranabant is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Taranabant is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Taranabant is combined with Acetophenazine.
AclidiniumThe risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Taranabant.
AgomelatineThe risk or severity of adverse effects can be increased when Taranabant is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Taranabant is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Taranabant is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Taranabant is combined with Almotriptan.
AlosetronThe risk or severity of adverse effects can be increased when Taranabant is combined with Alosetron.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenylpropanes / Benzonitriles / Alkyl aryl ethers / Chlorobenzenes / Pyridines and derivatives / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Nitriles
show 6 more
Substituents
Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Benzonitrile / Carbonitrile
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
X9U622S114
CAS number
701977-09-5
InChI Key
QLYKJCMUNUWAGO-GAJHUEQPSA-N
InChI
InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
IUPAC Name
N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide
SMILES
C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N

References

General References
Not Available
ChemSpider
9401143
BindingDB
50200841
ChEMBL
CHEMBL220360
ZINC
ZINC000028701758
PDBe Ligand
7DY
Wikipedia
Taranabant
PDB Entries
5u09

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedPreventionObesity1
3TerminatedTreatmentObesity3
3TerminatedTreatmentObesity Type 2 Diabetes Mellitus / Type 2 Diabetes Mellitus1
2CompletedTreatmentObesity1
2CompletedTreatmentSmoking1
2CompletedTreatmentUrinary Incontinence (UI)1
2, 3CompletedTreatmentObesity and Obesity-related Medical Conditions1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000596 mg/mLALOGPS
logP6.03ALOGPS
logP6.8ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)1.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area75.01 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity132.14 m3·mol-1ChemAxon
Polarizability50.13 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at March 19, 2008 16:41 / Updated at February 21, 2021 18:52